Discontinued — last reported Q1 '25
Business Segments · Goodwill
Covance Drug Development — Goodwill
Labcorp Holdings Covance Drug Development — Goodwill increased by 1.8% to $1.29B in Q1 2025 compared to the prior quarter. Year-over-year, this metric grew by 1.3%, from $1.27B to $1.29B. Over 3 years (FY 2021 to FY 2024), Covance Drug Development — Goodwill shows a downward trend with a -27.6% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2013
Last reportedQ1 2025
Rolls up toGoodwill
How to read this metric
An increase suggests recent acquisitions, while a decrease may indicate impairment or divestitures.
Detailed definition
Represents the carrying value of goodwill associated with the drug development business segment. This asset reflects the...
Peer comparison
Standard across large healthcare service firms that grow through M&A.
Metric ID:
lh_segment_covance_drug_development_goodwillHistorical Data
16 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.92B | $3.88B | $1.84B | $4.02B | $3.93B | $3.79B | $1.59B | $3.60B | $1.61B | $1.59B | $1.33B | $1.27B | $1.28B | $1.33B | $1.27B | $1.29B |
| QoQ Change | — | -1.0% | -52.5% | +118.1% | -2.4% | -3.6% | -58.0% | +126.5% | -55.2% | -1.7% | -16.3% | -4.2% | +0.2% | +4.2% | -4.6% | +1.8% |
| YoY Change | — | — | — | — | +0.2% | -2.5% | -13.8% | -10.5% | -58.9% | -58.1% | -16.5% | -64.7% | -21.0% | -16.3% | -4.6% | +1.3% |
Range$1.27B – $4.02B
CAGR-25.7%
Avg YoY Growth-22.1%
Median YoY Growth-15.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's covance drug development — goodwill?
- Labcorp Holdings (LH) reported covance drug development — goodwill of $1.29B in Q1 2025.
- How has Labcorp Holdings's covance drug development — goodwill changed year-over-year?
- Labcorp Holdings's covance drug development — goodwill increased by 1.3% year-over-year, from $1.27B to $1.29B.
- What is the long-term trend for Labcorp Holdings's covance drug development — goodwill?
- Over 3 years (2021 to 2024), Labcorp Holdings's covance drug development — goodwill has grown at a -27.6% compound annual growth rate (CAGR), from $13.55B to $5.14B.
- What does covance drug development — goodwill mean?
- The total value of goodwill recorded for the drug development business segment.